Citizen Portal
Sign In

Get AI Briefings, Transcripts & Alerts on Local & National Government Meetings — Forever.

Subcommittee reports six additional measures favorably, including child-welfare and claims bills

Florida House Civil Justice and Claims Subcommittee · February 11, 2026

Loading...

AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

Beyond three heavily debated measures, the subcommittee favorably reported PCS/HB949 (child welfare), HB6509 (claims relief for Mark Legatta, amended), HB587 (medical review committees, technical amendment), and PCS/HB689 (narrow employer immunity for medical marijuana cases). Vote counts and amendment summaries listed.

The Civil Justice and Claims Subcommittee advanced several additional bills on Feb. 12. Highlights:

- PCS/HB 949 (Representative Salzman) — Child-welfare measure clarifying that evidence of acute or chronic parental drug abuse may constitute harm or neglect when a parent's intoxication creates ongoing risk to a child. Reported favorably, 15-0.

- HB 6509 (Representative Groh) — Claims bill for relief to the estate of Mark Legatta tied to alleged Florida Department of Transportation negligence. Sponsor reduced the requested relief in an amendment from $2.2 million to $1.2 million; amendment adopted and the committee reported the bill favorably, 14-0.

- HB 587 (Representative Barnaby) — Revises the definition of "medical review committee" for clarity and adjusts the effective date by amendment to Oct. 1, 2026; reported favorably, 14-0.

- PCS/HB 689 (Representative Oliver) — Limits civil liability for employers where adverse action is taken related to medical-marijuana possession or use under narrow circumstances, while preserving the employer's ability to address reasonable-suspicion impairment; reported favorably, 11-3.

Each measure was accompanied by committee Q&A, limited public testimony or waivers of testimony, and, where applicable, technical or funding-related amendments. The committee adjourned following final votes.